JAK2 and myeloproliferative neoplasm: The JAK2 MV study suggests, along with others (38), that “CHIP-associated SVT” (38) or “SVT-predominant MPN” may become a novel clinical entity consisting of patients with abdominal venous thrombosis with the mutation JAK2 p.V617F.